source
- Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease dealHaving set Metsera on its journey to a $10 billion takeover, Arch Venture Partners and Population Health Partners have powered their new startup—Sentivera—to a licensing deal worth up to $1.5 billion.Fierce Biotech · 6h ago↗ source
- Neumora Therapeutics appoints Joshua Pinto as CEO and Doron Sagman as CMO ahead of IND filingNeumora Therapeutics announced leadership changes, naming Joshua Pinto, Ph.D., as its new chief executive officer. Pinto, who joined Neumora in 2021 as chief financial officer and most recently se…
- Pheast Therapeutics sticks with open R&D despite competitor Antengene moving ahead with anti‑CD24 trials